NCT06682156View on ClinicalTrials.gov

Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

March 31, 2028

Study Completion Date

June 30, 2028

Conditions
Newly Diagnosed Multiple Myeloma
Interventions
DRUG

Carfilzomib

carfilzomib C1: 20mg/m2，D1-2; 27mg/m2，D8-9; 36mg/m2，D15-16 C2 and subsequent cycles: 36mg/m2。

Trial Locations (1)

215006

RECRUITING

Lingzhi Yan, Suzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Soochow University

OTHER